 IRVINE, CA ACCESSWIRE July 17, 2020 Hancock Jaffe Laboratories, Inc. HJLI, a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a 5.6 million offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of approximately 5.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the company. The public offering is comprised of 12,500,000 units, priced at a public offering price of 0.32 per unit, with each unit consisting of one share of common stock and a seven year warrant to purchase one share of common stock at an exercise price of 0.32 per share. In a concurrent private placement, certain investors have agreed to purchase 1,556,000 of shares of Series C Convertible Preferred Stock priced at market and which are convertible into 6,078,125 shares of common stock and ii unregistered seven year warrants to purchase 6,078,125 shares of common stock with an exercise price of 0.32 per share. 